Aligos Therapeutics, Inc. (ALGS)
Largest Insider Buys in Sector
ALGS Stock Price History Chart
ALGS Stock Performance
About Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Insider Activity of Aligos Therapeutics, Inc.
Over the last 12 months, insiders at Aligos Therapeutics, Inc. have bought $6M and sold $0 worth of Aligos Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Aligos Therapeutics, Inc. have bought $13.13M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Nuechterlein Carole () — $6M.
The last purchase of 7,933,601 shares for transaction amount of $6M was made by Nuechterlein Carole () on 2023‑10‑25.
List of Insider Buy and Sell Transactions, Aligos Therapeutics, Inc.
| 2023-10-25 | Nuechterlein Carole | 7.93M 22.4566% | $0.76 | $6M | +13.90% | |||
| 2020-10-20 | Vivo Capital VIII, LLC | 10 percent owner | 550,000 1.9863% | $15.00 | $8.25M | +61.44% | ||
| 2020-10-20 | Novo Holdings A/S | 10 percent owner | 200,000 0.7223% | $15.00 | $3M | +61.44% | ||
| 2020-10-20 | Woiwode Thomas | director | 200,000 0.7223% | $15.00 | $3M | +61.44% | ||
| 2020-10-20 | Versant Venture Capital VI, L.P. | director | 400,000 1.4446% | $15.00 | $6M | +61.44% |
Insider Historical Profitability
| Nuechterlein Carole | 11025941 14.1016% | $0.40 | 1 | 0 | ||
| Vivo Capital VIII, LLC | 10 percent owner | 3116658 3.986% | $0.40 | 1 | 0 | +61.44% |
| Novo Holdings A/S | 10 percent owner | 2614563 3.3439% | $0.40 | 1 | 0 | +61.44% |
| Woiwode Thomas | director | 862444 1.103% | $0.40 | 1 | 0 | +61.44% |
| Versant Venture Capital VI, L.P. | director | 862444 1.103% | $0.40 | 1 | 0 | +61.44% |
Institutional Investor Ownership
| Armistice Capital Llc | $6.76M | 8.82 | 6.89M | +0.87% | +$58,344.30 | 0.08 | |
| Ecor1 Capital Llc | $6.26M | 8.18 | 6.39M | 0% | +$0 | 0.16 | |
| Deep Track Capital Lp | $5.98M | 7.81 | 6.1M | 0% | +$0 | 0.03 | |
| Vivo Capital | $3.48M | 4.54 | 3.55M | 0% | +$0 | 0.31 | |
| Adage Capital Partners Gp L L C | $2.42M | 3.16 | 2.46M | New | +$2.42M | <0.01 | |
| Versant Ventures | $2.27M | 2.97 | 2.32M | 0% | +$0 | 3.17 | |
| Baker Bros Advisors LP | $2.03M | 2.66 | 2.08M | 0% | +$0 | 0.03 | |
| Hillhouse Capital Advisors Ltd | $1.87M | 2.44 | 1.91M | 0% | +$0 | 0.04 | |
| Tang Capital Management, LLC | $1.62M | 2.11 | 1.65M | -24.65% | -$529,050.06 | 0.01 | |
| Opaleye Management Inc | $1.6M | 2.09 | 1.63M | +25.68% | +$326,340.00 | 0.25 | |
| Newtyn Management | $1.18M | 1.54 | 1.2M | -4.38% | -$53,900.00 | 0.26 | |
| Bank of America | $1.12M | 1.47 | 1.15M | <0.01% | -$34.30 | <0.0001 | |
| The Vanguard Group | $992,806.00 | 1.3 | 1.01M | +0.14% | +$1,387.68 | <0.0001 | |
| Renaissance Technologies | $792,000.00 | 1.04 | 808,260 | +64.96% | +$311,896.67 | <0.01 | |
| Pivotal Bioventure Partners Investment Advisor Llc | $728,351.00 | 0.95 | 743,215 | 0% | +$0 | 0.53 | |
| Acadian Asset Management | $644,000.00 | 0.84 | 657,995 | +17.63% | +$96,530.26 | <0.01 | |
| Silverarc Capital Management Llc | $642,405.00 | 0.84 | 655,515 | -1.94% | -$12,737.07 | 0.19 | |
| Ubs Oconnor Llc | $490,000.00 | 0.64 | 500,000 | New | +$490,000.00 | 0.04 | |
| Geode Capital Management | $365,674.00 | 0.48 | 373,056 | +16.2% | +$50,982.79 | <0.0001 | |
| BlackRock | $297,680.00 | 0.39 | 303,755 | +2.57% | +$7,463.68 | <0.0001 | |
| Citadel Advisors LLC | $279,965.00 | 0.37 | 285,679 | New | +$279,965.00 | <0.0001 | |
| Millennium Management LLC | $108,448.00 | 0.14 | 110,661 | +285.51% | +$80,317.04 | <0.0001 | |
| State Street | $95,475.00 | 0.13 | 97,423 | 0% | +$0 | <0.0001 | |
| Bridgeway Capital Management | $90,160.00 | 0.12 | 92,000 | 0% | +$0 | <0.01 | |
| Northern Trust | $90,175.00 | 0.12 | 92,015 | +70.5% | +$37,286.18 | <0.0001 | |
| Xtx Topco Ltd | $43,974.00 | 0.06 | 44,871 | +74.3% | +$18,745.62 | <0.01 | |
| Atom Investors Lp | $33,490.00 | 0.04 | 34,173 | New | +$33,490.00 | <0.01 | |
| Charles Schwab | $30,755.00 | 0.04 | 31,383 | 0% | +$0 | <0.0001 | |
| Choate Investment Advisors | $23,520.00 | 0.03 | 24,000 | 0% | +$0 | <0.01 | |
| Procyon Advisors Llc | $19,600.00 | 0.03 | 20,000 | New | +$19,600.00 | <0.01 | |
| HarbourVest Partners | $18,407.00 | 0.02 | 18,783 | 0% | +$0 | 0.01 | |
| Two Sigma | $18,252.00 | 0.02 | 18,624 | 0% | +$0 | <0.0001 | |
| CWM LLC | $17,000.00 | 0.02 | 16,891 | 0% | +$0 | <0.0001 | |
| Creative Planning | $15,215.00 | 0.02 | 15,525 | +54.48% | +$5,365.68 | <0.0001 | |
| ZWJ Investment Counsel | $14,210.00 | 0.02 | 14,500 | New | +$14,210.00 | <0.01 | |
| Zullo Investment Group Inc | $12,740.00 | 0.02 | 13,000 | 0% | +$0 | 0.01 | |
| Vontobel Holding Ltd | $12,250.00 | 0.02 | 12,500 | New | +$12,250.00 | <0.0001 | |
| UBS | $10,609.00 | 0.01 | 10,825 | New | +$10,609.00 | <0.0001 | |
| Financial Advocates Investment Management | $9,800.00 | 0.01 | 10,000 | New | +$9,800.00 | <0.0001 | |
| Total Clarity Wealth Management, Inc. | $9,800.00 | 0.01 | 10,000 | New | +$9,800.00 | <0.01 | |
| Tower Research Capital | $7,862.00 | 0.01 | 8,022 | -57.17% | -$10,492.47 | <0.0001 | |
| Morgan Stanley | $3,234.00 | <0.01 | 3,300 | +65% | +$1,274.00 | <0.0001 | |
| Simplex Trading Llc | $1,000.00 | <0.01 | 1,104 | New | +$1,000.00 | <0.0001 | |
| JPMorgan Chase | $663.00 | <0.01 | 677 | 0% | +$0 | <0.0001 | |
| Wells Fargo | $292.00 | <0.01 | 298 | +1.71% | +$4.90 | <0.0001 | |
| Royal Bank of Canada | $0 | <0.01 | 124 | -71.88% | -$0 | <0.0001 | |
| Qube Research & Technologies | $2.00 | <0.01 | 2 | 0% | +$0 | <0.0001 |